Led · Series D · Aug 2026

Craif develops a urine analysis platform that combines proprietary biomarker detection and AI to assess disease risk, with cancer as its initial focus. Its flagship test, miSignal, is available at more than 2,500 medical institutions and 4,500 pharmacies in Japan, and the company has performed over 110,000 tests to date. Craif analyzes microRNA signals and has published more than 90 peer-reviewed papers and conference presentations, including two independent publications on early pancreatic cancer detection. The company is advancing a software-based medical device program targeting pancreatic cancer and plans a prospective clinical study in the U.S. from its San Diego laboratory. Craif opened its San Diego lab in April 2026, established a U.S. subsidiary in 2022, and is building clinical, regulatory, and commercial capabilities to support a reimbursement-driven U.S. launch.

Led · Series B · Aug 2026

Founded in 2023, Aureka builds large biological foundation models (AuraIDE and its open-source counterpart OpenDDE) and integrates them with Lab-in-the-Loop — a closed-loop system combining AI agents, digital biology and high-throughput experimental platforms. Its foundation models are trained on proprietary protein co-evolution data and evaluated as among the leaders in protein structure prediction and de novo molecular design. The company reports generating tens of millions in revenue over the past two years and has established strategic partnerships with multiple global pharmaceutical companies. Aureka’s platform couples model-driven molecular generation with in-house single-cell functional screening and automated wet-lab validation, feeding experimental results back into model post-training to iterate rapidly. With the Series B proceeds, Aureka plans to scale model training, upgrade its experimental feedback engine, accelerate validation and translate model capabilities into antibody drug assets.

Led · Equity · Jul 2026

Omio operates a multimodal travel distribution platform that lets travelers search, compare and book journeys across rail, air, bus and ferry. The company sells more than 100,000 tickets daily, employs over 470 staff from more than 50 countries, and maintains offices including locations in Singapore and Bangalore. Omio’s portfolio includes Omio consumer and B2B offerings, Rome2Rio, and, pending completion, Rail Europe. It is expanding its transport network and partnerships in Japan and Southeast Asia, citing strong demand on routes such as the Golden Route and more remote destinations. Omio plans to grow regional teams, strengthen local operator partnerships (including Kōbe and Willer Express), and leverage its AI-focused technology hub in Singapore. The company aims to be in more than 70 markets worldwide by 2028.

Participated · Series B · May 2026

Tianji Intelligence has built a full-stack R&D and mass production system spanning core sensors, integrated joints, controllers and a product matrix handling loads from 3kg to 20kg. It is the first embodied intelligence company to develop its own MEMS joint torque sensors and deploy them in robot joints and has engineered a "one-drive-two" coordination architecture to synchronize two 7-axis force-control arms from a single motherboard. Tianji's Marvin force-control humanoid dual-arm has demonstrated latency as low as 5ms and an average error of 1.89mm in recent tests. Its lightweight integrated joint module, the Marvin M6S Lite, achieves a 62.5% load-to-weight ratio, weighing 8kg while handling a 5kg payload and offering an 8kHz torque closed loop with four-loop control. In the first four months of 2025 the company delivered over 2,000 force-control humanoid dual arms to more than 100 clients, became the largest shipper globally by volume for such systems, and reported backlog orders exceeding 10,000 units in Q1. Its customer base includes 45 global humanoid robot OEMs and other embodied intelligence unicorns, and the company aims to use scale and the new funding to expand R&D, production and global sales.

Participated · Series B · May 2026

Founded in 2021, Hypershell develops consumer-grade mechanical exoskeletons combining lightweight materials, patented architecture, and AI-driven motion algorithms. The company launched its first product via Kickstarter in 2023, raising $1.23 million, and has since shipped tens of thousands of units across more than 70 countries. Its product family includes the X series—featuring the single-motor-driven Omega architecture, the AI MotionEngine™ and HyperIntuition™ algorithms—achieving product weights around 1.8 kg, motor peak power up to 800W, and typical battery ranges of 15–17.5 km; the X Ultra is priced around 10,000 yuan. Hypershell’s X Carbon and X Ultra have won CES and IFA innovation awards, and the company has secured third-party certifications from SGS and TÜV Rheinland. The company maintains a team of nearly 200 people with over 70% in R&D and holds hundreds of core technologies and patents, supporting its mass-production and global sales footprint.